AnaptysBio (LTS:0HFQ) FFO


LTS:0HFQ AnaptysBio Inc LTS:0HFQ
67 GF Score
Price $60.33
GF Value $58.93
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is AnaptysBio FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0HFQ
67GF Score
AnaptysBio Inc LTS:0HFQ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AnaptysBio (LTS:0HFQ) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of $60.33 is trading 2.4% above its estimated GF Value™ of $58.93. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for LTS:0HFQ:

  • FFO:
  • GF Value™: $58.93 vs. price of $60.33 (2.4% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LTS:0HFQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges ANAB:USAAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score

Get the complete analysis for LTS:0HFQ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.33
Price
$58.93
GF Value